BIOMAT Database Logo BIOMAT Database Logo

Retrospective evaluation of pubertal development and linear growth of girls with Turner Syndrome treated with oral and transdermal estrogen. 2015

Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım

OBJECTIVE The objective of the study was to evaluate the pubertal development and linear growth of Turner Syndrome (TS) girls regularly monitored in our department. METHODS The data of 13 patients with TS were evaluated retrospectively. Left hand radiograms were evaluated by three different pediatric endocrinologists to determine bone ages. RESULTS Six (46.2%) of the TS girls were treated with oral estrogens, while 7 (53.8%) were treated with transdermal estrogen. The ratios of chronological age (CA) difference to bone age (BA) difference (ΔCA/ΔBA) in two groups of patients treated with estrogen were compared at the time of the last control. The ΔCA/ΔBA ratio in the transdermal estrogen-treated group was significantly higher (p=0.005). These results suggest slower BA progression in the TS girls treated with transdermal estrogen. CONCLUSIONS BA advancement is less significant with transdermal estrogen, which is associated with adequate breast development.

UI MeSH Term Description Entries
D011627 Puberty A period in the human life in which the development of the hypothalamic-pituitary-gonadal system takes place and reaches full maturity. The onset of synchronized endocrine events in puberty lead to the capacity for reproduction (FERTILITY), development of secondary SEX CHARACTERISTICS, and other changes seen in ADOLESCENT DEVELOPMENT. Puberties
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with turner syndrome.
November 2007, The Journal of clinical endocrinology and metabolism,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Growth during pubertal induction in girls with Turner Syndrome: a retrospective cohort analysis.
February 2024, The Journal of clinical endocrinology and metabolism,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study.
June 2009, The Journal of clinical endocrinology and metabolism,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Pubertal induction in girls with Turner Syndrome.
December 2021, Minerva endocrinology,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy.
January 2019, Hormone research in paediatrics,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Delayed spontaneous pubertal growth spurt in girls with Ullrich-Turner syndrome.
September 1992, American journal of medical genetics,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Abnormal Uterine Bleeding during Pubertal Induction with Transdermal Estrogen in Individuals with Turner Syndrome.
August 2023, Journal of pediatric and adolescent gynecology,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
[Effect of estrogen therapy on the growth of Turner syndrome in girls treated with growth hormone].
January 2001, Medicina,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Delayed spontaneous pubertal growth spurt in girls with the Ullrich-Turner syndrome.
September 1991, American journal of medical genetics,
Esra D P Çakır, and Halil Sağlam, and Erdal Eren, and Taner Özgür, and Ömer F Tarım
Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndrome.
November 2011, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!